The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large internat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058241/
https://ncbi.nlm.nih.gov/pubmed/30037803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019414
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars